



UNITED STATES PATENT AND TRADEMARK OFFICE

Commissioner for Patents
United States Patent and Trademark Office
P.O. Box 1450
Alexandria, VA 22313-1450
www.uspto.gov

LORI L. KERBER
INCYTE CORPORATION
3160 PORTER DRIVE
PALO ALTO, CALIFORNIA 94304

In re Application of	:
Tang et al.	:Petition to Review Lack of Unity
Serial No: 09/700,590	:Under 37 C.F.R. 1.144
Filed: 16 April 2001	:
Attorney Docket No: PF-0526 USN	:

This is in response to applicant's petition under 37 CFR 1.144, filed 29 March 2004, requesting review of the Examiner's lack of unity requirement mailed 25 July 2001.

BACKGROUND

This application is a U.S. national stage application properly filed under 35 USC 371.

The Examiner instituted a lack of unity requirement of claims 1-20 into 8 groups and required a selection of a single sequence for examination in an Office action which was subsequently made final. In particular, the following lack of unity between Group II and Group I is at issue:

Group I, claims 1,2, 15, drawn to polypeptide having SEQ ID NO:101.

Group II, claims 3, 6, 9-14, drawn to polynucleotide encoding SEQ ID NO:101 or having SEQ ID NO 22.

In the response dated 23 December 2003 to the lack of unity requirement Applicant elected, with traverse, Group II and polynucleotides encoding polypeptide SEQ ID NO:101 including the nucleotide SEQ ID NO:22. The examiner then considered the traversal, found it not persuasive and made the lack of unity holding final.

RELEVANT AUTHORITY

An international or a national stage application are considered to have unity of invention where there exists a “special technical feature” that defines a contribution which each of the claimed inventions, considered as a whole, makes over the prior art. See PCT Rule 13.2; 37 CFR 1.475(a), (b)(1) and (2).

PCT Rule 13.2 Circumstances in Which the Requirement of Unity of Invention Is to Be Considered Fulfilled

Where a group of inventions is claimed in one and the same international application, the requirement of unity of invention referred to in Rule 13.1 shall be fulfilled only when there is a technical relationship among those inventions involving one or more of the same or corresponding special technical features. The expression “special technical features” shall mean those technical features that define a contribution which each of the claimed inventions, considered as a whole, makes over the prior art.

PCT Administrative Instructions, Annex B, Part 2, Example 17 states:

Claim 1: Protein X

Claim 2: DNA sequence encoding protein X.

Expression of the DNA sequence in a host results in the production of a protein which is determined by the DNA sequence. The protein and the DNA sequence exhibit corresponding special technical features. Unity of invention between claims 1 and 2 is accepted.

Unity of invention has to be considered in the first place only in relation to the independent claims in an international application and not the dependent claims.

DISCUSSION

Applicant’s petition and the file record have been carefully considered.

Applicants are correct that the above-identified application is a national stage application submitted under 35 U.S.C. 371 to which “unity of invention”, and not U.S. restriction practice is applicable. See MPEP section 1893.03(d). The lack of unity between independent polypeptide claims of Group I and independent polynucleotide claims of Group II is therefore at issue.

Independent claim 21 (corresponding to Group I) and claim 31 (corresponding to Group II) are reproduced below:

21. An isolated polypeptide selected from the group consisting of:
 - a) a polypeptide comprising the amino acid sequence of SEQ ID NO:22,
 - b) a polypeptide comprising a naturally occurring amino acid sequence at least 90% identical to the amino acid sequence of SEQ ID NO:22,

- c) a biologically active fragment of a polypeptide having the amino acid sequence of SEQ ID NO:22, and
- d) an immunologically active fragment of a polypeptide having the amino acid sequence of SEQ ID NO:22, wherein said immunologically active fragment generates an antibody that specifically binds to SEQ ID NO:22.

31. An isolated polynucleotide selected from the group consisting of:

- a) a polynucleotide comprising the polynucleotide sequence of SEQ ID NO:101,
- b) a polynucleotide comprising a naturally occurring polynucleotide sequence at least 90% identical to the polynucleotide sequence of SEQ ID NO:101,
- c) a polynucleotide complementary to a polynucleotide of a),
- d) a polynucleotide complementary to a polynucleotide of b), and
- e) an RNA equivalent of a)-d).

Applicant argues that in accordance with PCT Administrative Instructions, Example 17, the claims of Group I and Group II should possess unity of invention. Applicants have argued and added emphasis to the following sentence of Example 17:

The protein and the DNA sequence exhibit corresponding special technical features.

Applicants appear to be arguing that this sentence is a conclusion directed at any particular combination of DNA and protein inventions. This is not persuasive. This sentence is understood to present background facts relating to this particular example which specifies that in these claims, the DNA encodes the protein, the DNA and protein make a contribution over the prior art. In the inventions of Example 17, the groups share a technical feature which makes a contribution over the prior art, therefore, unity is accepted.

Applicant's argument is misplaced since PCT Rule 13.2 and Example 17 specifically indicates that unity of invention between the protein and its corresponding encoding nucleotide sequence requires that the protein and the DNA sequence exhibit corresponding special technical features, i.e., make a contribution over the prior art.

The inventions under consideration here do not fit into the pattern of Example 17 and therefore are not considered to have unity of invention for the following reasons. It is first noted that the representative claims 21 and 31 above are drawn to a genus of nucleotides encoding a genus of polypeptides and not a genus of nucleotides encoding a single protein as in Example 17. Accordingly, in the first instance, unity of invention pursuant to Example 17 may not be applicable.

With regard to the isolated polynucleotides of claim 31, it is first noted these polynucleotides lack the functional limitation required by Example 17 since the polynucleotides of claim 31 are not required to encode any polypeptide. Claim 31(b) defines the polynucleotide only in terms of partial structure and reads upon polynucleotides which are at least 90% identical to SEQ ID NO:101. A polynucleotide containing a stop codon truncating the open reading frame or the presence of a splice site which results in an open reading frame shift would fit into the required structural limitation but it would not encode the polypeptide having at least 90% identity to SEQ

ID NO:22. The complementary sequences encompassed by parts (c) and (d) of claim 31 are non-coding strands of any length. Transcription and translation of a non-coding strand would not result in the polypeptide having SEQ ID No 22. Within the large numbers of polynucleotides encompassed by Claim 31, many which could encode a polypeptide would not encode the polypeptides of Group I. For these reasons, Groups I and II lack a same or corresponding technical feature, as required by PCT Rule 13.2. The protein invention and the polynucleotide invention lack a one-to-one correspondence.

Even if the polynucleotides and polypeptides shared a same or corresponding technical feature, they do not both make a contribution over the prior art. The attached sequence alignment shows a polypeptide sequence which is 99.7 % identical to SEQ ID NO 22. See the alignment of SEQ ID NO 22 with Accession Number Y12059, submitted to Genbank on 2 May 1998, which is prior to the earliest claimed priority date of 29 May 1998. Claim 21, part (b) encompasses polypeptides which are 90% identical to SEQ ID No 22.

For these reasons, the lack of unity of invention between the polypeptide and the polynucleotide is maintained.

DECISION

Applicant's petition to withdraw the lack of unity requirement between Groups I and II under 37 CFR 1.144 is **DENIED** for the reasons set forth above.

The application will be forwarded to the Examiner for consideration of the Appeal Brief filed on 8 April 2004


Any request for consideration must be filed within two (2) months of the mailing date of this decision.

Should there be any questions regarding this decision, please contact Special Program Examiner Julie Burke, by mail addressed to Director, Technology Center 1600, PO BOX 1450, ALEXANDRIA, VA 22313-1450, or by telephone at (571) 272-1600.



Jasemine Chambers
Director, Technology Center 1600.

HSHUNKI		3149 bp	mRNA	linear	PRI 02-MAY-1998
LOCUS	HSHUNKI				
DEFINITION	H. sapiens HUNKI mRNA.				
ACCESSION	Y12059				
VERSION	Y12059.1				
KEYWORDS	GI:3115203				
SOURCE	HUNKI gene.				
ORGANISM	Homo sapiens.				
	Homo sapiens				
REFERENCE	Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;				
AUTHORS	1 (bases 1 to 3149)				
JOURNAL	Mammalia; Rutheria; Primates; Catarrhini; Homnidae; Homo.				
REFERENCE	Weber, B.				
AUTHORS	2 (bases 1 to 3149)				
TITLE	Weber, B.				
JOURNAL	Direct Submission				
	Submitted (24-MAR-1997) B. Weber, Labor Paediatriche				
	Molekularbiologie, Universitaetsklinikum Charite, Ziegelstr. 5-9,				
	10098 Berlin, FRG				
FEATURES	Location/Qualifiers				
source	1. 3149				
	/organism="Homo sapiens"				
	/db xref="taxon:9606"				
gene	223..2391				
	/tissue type="placenta"				
	223..2391				
	/gene="HUNKI"				
CDS	223..2391				
	/gene="HUNKI"				
	/note="strong homology to human RING3 sequence"				
	/codon start=1				
	/protein id="CAA72780.1"				
	/db xref="GI:3115204"				
	/db xref="SPRMBL:O60885"				
	/translation="MSASGSGPTLRNLNPMVMDGLTSSMTTQAOAQQPANAASTN				
	PPPEPSPNKPGRQTNLOYLVLVLTAKHQFAMPFOQVDAVKLANLPDYKILK				
	TPMDGTGIIKKLENNYVNAQSCIQDPTMTNICYIYNKFGDDIVLMAEAKELQK				
	INELPTSEIIMIVQANGRGKRGITGAKGVSNVTNTOASTPTGTQTPQNPFPV				
	QATPHPPVLPDILVQTPVTVPVPPPLQTPPTTPIIDIEHPEPLPPEPKTKLGRRESSRPVKPKKD				
	ATQPVNKTGKGVKRAADITPTTIDIEHPEPLPPEPKTKLGRRESSRPVKPKKD				
	VPSQHPAPPEKSKVSEGLKCCSGILKEMFAKHAAYAWPFYKPDVVEALGLHDYCD				
	IIKHPMDDSTIKSLREARYDAQFGADVRLMFNCTYKTPPDHVVAMARKLQDVF				
	EMRPAKQDPPEEPVAVSVPVPTKVAAPPSSSSSSSSSSSSSSSSSSSSSSSSSS				
	ORLAELQELQALVHEQLAALSOQNKPKKCKKCKKCKKCKKCKKCKKCKKCKKCK				
	EPPEKTKNNSSNVSKKBPAPMKSKPPTTYSBEDCKKPKKPKKPKKPKKPKKPKK				
	LPKELGRVHIIQSPERSIKNSNPDEIETDPTLKPSLTRELLERYVTSCLKRKPKQ				
	AKPDVIVAGSKKNGFSS				
BASE COUNT	818 a 946 c 788 g 597 t				
ORIGIN					
Alignment Scores:					
Pred. No.:	1.92e-138	Length:	3149		
Score:	3583.00	Matches:	686		
Percent Similarity:	99.71%	Conservative:	0		
Best Local Similarity:	99.71%	Mismatches:	2		
Query Match:	98.46%	Indels:	2		
DB:	9	Gaps:	0		
US-09-700-590A-22 (1-688) x HSHUNKI (1-3149)					
Qy	1 MetSerAlaGluSerGlyProGlyThrArgLeuArgAsnLeuProValMetGlyAspGly	20			
Db	223 ATGTCTGGCGAGAGCGCGCTGGGACGAGATTGGAATCTGCCAGTAAATGGGGATGGA	282			
Qy	21 LeuGluThrSerGlnMetSerThrThrGlnAlaGlnAlaGlnProGlnProAlaAsnAla	40			
Db	283 CTAGAAACTTCTCCAAATGCTACACACACAGCCCGCCAGCCCAACCCAGCAGCAACGCA	342			
Qy	41 AlaSerThrAsnProProProGluThrSerAsnProAsnProAsnProAsnProAsnPro	60			
Db	343 GCACGACCCACACCCCGCCCGCCCGCCCGCCCGCCCGCCCGCCCGCCCGCCCG	402			
Qy	61 AsnGlnLeuGlnTyrLeuLeuArgValValLeuLysThrLeuTyrLysHisGlnPheAla	80			



□1: Y12059. *H.sapiens* HUNKI m...[gi:3115203] Links

1	attcttttga	atactactgc	tagaagtctg	acttaagacc	cagcttatgg	gccacatggc
61	acccagctgc	ttctgcagag	aaggcaggcc	actgatgggt	acagcaaagt	gtggtgctgc
121	tggccaagcg	aaagaccctg	gtaggatgat	tgggcctctg	ccccttgtgg	gtgtgtccac
181	tgtctgttag	tgccctggtg	agaatgtgat	gggatcacta	gcattgtctg	ggagagcggc
241	cctgggacga	gattgagaaa	tctgccagta	atgggggatg	gactagaaac	ttcccaaagt

```

301 tctacaacac aggcccaggc ccaaccccag ccagccaacg cagccagcac caaccccccg
361 cccccagaga cctccaaccc taacaagccc aagaggcaga ccaaccaact gcaatacctg
421 ctcagagtgg tgctcaagac actatggaaa caccagtttg catggccttt ccagcagcct
481 gtggatgccg tcaagctgaa cctccctgat tactataaga tcattaaaac gcctatggat
541 atgggaacaa taaagaagcg cttggaaaac aactattact ggaatgctca ggaatgtatc
601 caggacttca acactatggt tacaaattgt tacatctaca acaagcctgg agatgacata
661 gtcttaatgg cagaagctct ggaaaagctc ttcttgcaaa aaataaatga gctaccaca
721 gaagaaaccg agatcatgat agtccaggca aaaggaagag gacgtgggag gaaagaaaaca
781 gggacagcaa aacctggcgt ttccacggta ccaaacacaa ctcaagcatc gactcctccg
841 cagaccacga cccctcagcc gaatcctcct cctgtgcagg ccacgcctca ccccttcctc
901 gccgtcaccg cggacctcat cgtccagacc cctgtcatga cagtggtgcc tcccagcca
961 ctgcagacgc ccccgccagt gcccccccag ccacaacccc caccgcctcc agctcccag
1021 cccgtacaga gccaccacc catcatcgcg gccaccacac agcctgtgaa gacaaagaag
1081 ggagtgaaga ggaaagcaga caccaccacc cccaccacca ttgaccccat tcacgagcca
1141 ccctcgctgc ccccgagcc caagaccacc aagctggggc agcggcggga gagcagccgg
1201 cctgtgaaac ctccaaagaa ggacgtgccc gactctcagc agcaccagc accagagaag
1261 agcagcaagg tctcggagca gctcaagtgc tgcagcggca tcctcaagga gatgtttgcc
1321 aagaagcacg ccgcctacgc ctggcccttc tacaagcctg tggacgtgga ggcactgggc
1381 ctacacgact actgtgacat catcaagcac cccatggaca tgagcacaat caagtctaaa
1441 ctggaggccc gtgagtaccg tgatgtcagc gagtttggtg ctgacgtccg attgatgttc
1501 tccaactgct ataagtacaa ccctcctgac catgagggtg tggccatggc ccgcaagctc
1561 caggatgtgt tcgaaatgcy ctttgccaag atgccggacg agcctgagga gccagtgggtg
1621 gccgtgtcct ccccggcagt gccccctccc accaaggttg tggccccgcc ctcatccagc
1681 gacagcagca gcgatagctc ctccgacagt gacagttcga ctgatgactc tgaggaggag
1741 cgagcccagc ggctggctga gctccaggag cagctcaaaag ccgtgcacga gcagcttgca
1801 gccctctctc agccccagca gaacaaacca aagaaaaagg agaaagacaa gaaggaaaag
1861 aaaaaagaaa agcacaaaag aaaagaggaa gtggaagaga ataaaaaaag caaagccaag
1921 gaacctctc ctaaaaagac gaagaaaaat aatagcagca acagcaatgt gagcaagaag
1981 gagccagcgc ccatgaagag caagccccct cccacgtatg agtcggagga agaggacaag
2041 tgcaagccta tgtcctatga ggagaagcgg cagctcagct tggacatcaa caagctcccc
2101 ggcgagaagc tgggccgcgt ggtgcacatc atccagtcac gggagccctc cctgaagaat
2161 tccaaccccg acgagattga aatcgacttt gagaccctga agccgtccac actgctgag
2221 ctggagcgt atgtcacctc ctgtttgcgg aagaaaagga aacctcaagc tgagaaagtt
2281 gatgtgattg ccggctcctc caagatgaag ggcttctcgt cctcagagtc ggagagctcc
2341 agtgagtcca gctcctctga cagcgaagac tccgaaacag gtcctgccta atcattggac
2401 acggactctt aataaaacgg tcttcagttc cagattcctt cccagcaagc tatagcttaa
2461 gtccattttc ttccgtgaaa gggacaggac tccatcaagt tatggaattc ctcagagccc
2521 tgggcctgtc ccccggggtg gattagtcac gtccagcagc acacgcctag tcccgccttc
2581 gggaaggctg cctgcctggc cagccgccc aagcctctctg tgtaaagact gcctggctgt
2641 cctgcccagc cttcctggtt ctctggggtc ctctgggttg gtggcatctc ctggagggtg
2701 atgacaatcc ccaacacatg cattcatgtg gtgctactct gtgtgcaaag ccagacccca
2761 agtatgtttt ctctctttgt cccatccctc ttttctggg actttggacc ctaactactt
2821 ccctcctgaa ccttgacgtg acatcagtc aggagagctc tcgttcagtg tgcggaagaa
2881 cactctgacc tctagagctg tcctagataa ggagtgggag ctttagaggc aaggcctcta
2941 gacctggaa ggctcagtga ggctcttccc acagcatgct tctcactggt gccctgtaag
3001 ctcgagccac cgctgactct gagccttttt ggagtccttc ctcttcgtc tccattgttc
3061 cgtgcatttc caaagcttaa gttgctggtg ggcatttccc cagtttctat gggctccgtc
3121 ttctcaagtc acatagggaa agtaccttc

```

//

[Disclaimer](#) | [Write to the Help Desk](#)
[NCBI](#) | [NLM](#) | [NIH](#)

May 12 2004 07:05:19